{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:43:08Z","timestamp":1740163388775,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s13555-017-0216-z","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T01:44:57Z","timestamp":1512092697000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report"],"prefix":"10.1007","volume":"8","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiss","family":"Lassoued","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maifa","family":"Belghoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Debbache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7547-3783","authenticated-orcid":false,"given":"Bachra","family":"Choufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"216_CR1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866\u201373.","journal-title":"Nature"},{"key":"216_CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u0148as M, Kreueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"Suppl 93","key":"216_CR3","first-page":"S2","volume":"33","author":"W Alwan","year":"2015","unstructured":"Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(Suppl 93):S2\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"216_CR4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dth.12251","volume":"28","author":"AA Gaspari","year":"2015","unstructured":"Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28:179\u201393.","journal-title":"Dermatol Ther"},{"key":"216_CR5","first-page":"1","volume":"13","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Saraceno R, Novelli L, et al. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010\u20132015). Expert Opin Ther Pat. 2016;13:1\u201310.","journal-title":"Expert Opin Ther Pat"},{"key":"216_CR6","first-page":"913","volume":"11","author":"SG Kwatra","year":"2012","unstructured":"Kwatra SG, Dabade TS, Gustafson CJ, Feldman SRJ. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012;11:913\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 2","key":"216_CR7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/10428194.2011.565435","volume":"52","author":"TA Summers","year":"2011","unstructured":"Summers TA, Jaffe ES. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma. 2011;52(Suppl 2):6\u201310.","journal-title":"Leuk Lymphoma"},{"key":"216_CR8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.blre.2014.06.003","volume":"28","author":"MR Grever","year":"2014","unstructured":"Grever MR, Blachly JS, Andriotos LA. Hairy cell leukemia: update on molecule profiling and therapeutic advances. Blood Rev. 2014;28:197\u2013203.","journal-title":"Blood Rev"},{"issue":"Suppl2","key":"216_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.570394","volume":"52","author":"JB Johnston","year":"2011","unstructured":"Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl2):43\u20135.","journal-title":"Leuk Lymphoma"},{"key":"216_CR10","doi-asserted-by":"crossref","first-page":"e0129182","DOI":"10.1371\/journal.pone.0129182","volume":"10","author":"M Korsen","year":"2015","unstructured":"Korsen M, Bragado Alonso S, Peix L, et al. Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS One. 2015;10:e0129182.","journal-title":"PLoS One"},{"key":"216_CR11","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1182\/blood-2009-05-224840","volume":"114","author":"DA Jacobsohn","year":"2009","unstructured":"Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a pediatric blood and marrow transplant consortium study. Blood. 2009;114:4354\u201360.","journal-title":"Blood"},{"key":"216_CR12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med"},{"key":"216_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","volume":"135","author":"JE Gudjonsson","year":"2004","unstructured":"Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135:1\u20138.","journal-title":"Clin Exp Immunol"},{"key":"216_CR14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/oxfordjournals.annonc.a059223","volume":"6","author":"PL Zinzani","year":"1995","unstructured":"Zinzani PL, Ricci P, Bendandi M, Tura S. 2-Chlorodeoxyadenosine in psoriasis treatment. Ann Oncol. 1995;6:509.","journal-title":"Ann Oncol"},{"key":"216_CR15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0190-9622(99)70373-7","volume":"41","author":"W Ilyas","year":"1999","unstructured":"Ilyas W, Myers D, Mann R, Seraly MP. Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia. J Am Acad Dermatol. 1999;41:316\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"216_CR16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s00277-002-0554-4","volume":"81","author":"J Valencak","year":"2002","unstructured":"Valencak J, Trautinger F, Fiebiger WC, Raderer M. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine. Ann Hematol. 2002;81:662\u20135.","journal-title":"Ann Hematol"},{"key":"216_CR17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/art.1780381112","volume":"38","author":"B Eibschutz","year":"1995","unstructured":"Eibschutz B, Weisman S, Amox M, et al. Oral 2-chlorodeoxyadenosine in psoriatic. Arthritis Rheum. 1995;38:1604\u20139. https:\/\/doi.org\/10.1002\/art.1780381112 .","journal-title":"Arthritis Rheum"},{"key":"216_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","volume":"2015","author":"M Duvic","year":"2015","unstructured":"Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome. Hematol Am Soc Hematol Educ Progr. 2015;2015:529\u201344.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"216_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12508","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Megna M, Patr\u00ec A, et al. Systemic treatment for psoriasis and malignancies: a real risk? Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12508 .","journal-title":"Dermatol Ther"},{"issue":"1","key":"216_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3315\/jdcr.2013.1126","volume":"7","author":"L Costanzo Di","year":"2013","unstructured":"Di Costanzo L, Ayala F, Megna M, Gaudiello F, Patr\u00ec A, Balato N. The risk of herpes zoster in the anti-TNF-\u03b1 era: a case report and review of the literature. J Dermatol Case Rep. 2013;7(1):1\u20134.","journal-title":"J Dermatol Case Rep"},{"key":"216_CR21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ibd.20410","volume":"14","author":"JB Brown","year":"2008","unstructured":"Brown JB, Lee G, Grimm GR, et al. Therapeutic benefit of pentostatin in severe IL-10\u2212\/\u2212 colitis. Inflamm Bowel Dis. 2008;14:880\u20137.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-017-0216-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T02:13:30Z","timestamp":1570414410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-017-0216-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1007\/s13555-017-0216-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}